drugset / Trial / NCT04069325

Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy

NCT04069325

RandomizedParallel-groupTriple-blindPrevention

Summary

The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.

Timeline

Start
2019-09-01
Primary completion
2020-07-28
Completion
2020-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject simiaowan Unknown 6 g Oral
Background Febuxostat Small molecule 40 mg Oral

Indications